Welcome to our dedicated page for Churchill Capital XI news (Ticker: CCXI), a resource for investors and traders seeking the latest updates and insights on Churchill Capital XI stock.
Our selection of high-quality news articles is accompanied by an expert summary from Rhea-AI, detailing the impact and sentiment surrounding the news at the time of release, providing a deeper understanding of how each news could potentially affect Churchill Capital XI's stock performance. The page also features a concise end-of-day stock performance summary, highlighting the actual market reaction to each news event. The list of tags makes it easy to classify and navigate through different types of news, whether you're interested in earnings reports, stock offerings, stock splits, clinical trials, fda approvals, dividends or buybacks.
Designed with both novice traders and seasoned investors in mind, our page aims to simplify the complex world of stock market news. By combining real-time updates, Rhea-AI's analytical insights, and historical stock performance data, we provide a holistic view of Churchill Capital XI's position in the market.
Agility Robotics appointed Michael Beer as Chief Financial Officer as it prepares for a planned public listing via its previously announced business combination with Churchill Capital Corp XI (NASDAQ: CCXI). Current CFO and COO Jennifer Hunter will transition to focus exclusively on the Chief Operating Officer role.
According to Agility Robotics, the leadership evolution creates dedicated executive oversight for finance and operations to support scaling production, global manufacturing and supply chain as customer deployments grow. Beer will lead capital markets, FP&A, accounting, treasury and investor relations. Agility reports deployments with Schaeffler, GXO and Toyota Motor Manufacturing Canada and a pipeline of over 30 enterprise customers across logistics, manufacturing and supply chain.
The company reiterates that its business combination with Churchill Capital Corp XI is expected to provide more than $620 million in gross proceeds, supporting expansion of production, customer deployments and its goal to operate as a publicly listed U.S. pure-play humanoid robotics company.
Agility, a humanoid robotics and Physical AI company, announced the opening of a new 60,000-square-foot facility in Fremont, California to serve as its software and capabilities hub. Engineering teams there will train, test, and advance AI technologies that enable its humanoid robot, Digit, to learn new skills and perform more complex tasks in customer environments.
The site will host nearly 200 employees across hardware, AI/ML software, and field operations and complements Agility’s RoboFab manufacturing facility in Salem, Oregon. According to Agility, it has active deployments with major enterprises and has secured more than $300 million of multi-year orders for Digit v5, subject to contractual milestones. The expansion comes ahead of its planned public listing via business combination with Churchill Capital Corp XI (NASDAQ: CCXI).
Agility Robotics and Churchill Capital Corp XI (NASDAQ: CCXI) have confidentially submitted a draft Form S-4 registration statement to the SEC for their previously announced proposed business combination. The deal would result in Agility becoming a publicly traded company, expected to list under ticker AGLT.
According to Agility Robotics, the transaction is expected to deliver over $620 million in gross proceeds, including about $421 million of Churchill XI trust cash (assuming no redemptions) and roughly $201 million of incremental equity financing. Proceeds are intended to fund existing orders, expand deployments, and scale production of the Digit v5 humanoid robot. Closing is targeted for 2026, subject to shareholder, regulatory, stock exchange and customary approvals.
Agility Robotics will go public via a merger with Churchill Capital Corp XI, valuing Agility at a $2.5 billion pre-money equity value. The deal is expected to provide over $620 million in gross proceeds, including a $200 million PIPE at $10 per share.
Agility reports over $300 million in multi-year Digit v5 orders, deployments across nine facilities with 65,000+ operating hours, and manufacturing capacity up to 10,000 humanoid robots annually. All existing shareholders will roll equity and be locked up for 180 days post-closing.
Churchill Capital Corp XI (Nasdaq: CCXI) said holders of units from its IPO may elect to separately trade Class A ordinary shares and warrants starting February 9, 2026. Only whole warrants will trade; no fractional warrants will be issued.
Separated Class A shares will trade as CCXI and warrants as CCXIW; unsplit units remain under CCXIU. This announcement is not an offer to sell or solicit purchases where unlawful.
Amgen has completed its acquisition of ChemoCentryx for $3.7 billion, or $52 per share, enhancing its inflammation portfolio with TAVNEOS (avacopan), a novel treatment for ANCA-associated vasculitis. TAVNEOS is FDA-approved and addresses a significant unmet medical need in autoimmune disease treatment. The acquisition also includes three early-stage candidates targeting inflammatory diseases and cancer.
ChemoCentryx, Inc. (Nasdaq: CCXI) announced planned presentations for TAVNEOS® (avacopan), a selective C5a receptor inhibitor, at upcoming conferences: the American Society of Nephrology Kidney Week 2022 and the American College of Rheumatology Convergence 2022. Key presentations will focus on data from the ADVOCATE trial, highlighting renal recovery and integrated safety in patients with ANCA-associated vasculitis. The FDA has approved TAVNEOS as an adjunctive therapy for severe active ANCA-associated vasculitis, crucial for patient management alongside glucocorticoids.
ChemoCentryx announced two poster presentations for CCX559, its investigational PD-L1 checkpoint inhibitor, at the SITC 37th Annual Meeting on November 10, 2022, in Boston, MA. The presentations include results from an ongoing Phase I clinical trial in advanced solid tumors and preclinical data from animal models. CCX559 shows promise by preferentially accumulating in tumors and depleting PD-L1, enhancing T cell activation. Following the Phase I trial, ChemoCentryx plans to enter a Phase Ib/II study in early 2023 to evaluate CCX559's anti-tumor effects.
ChemoCentryx, Inc. (Nasdaq: CCXI) announced poster presentations at three medical conferences showcasing TAVNEOS® (avacopan) for ANCA-associated vasculitis. The 18th European Meeting on Complement in Human Disease will feature seven posters from August 26-29 in Bern, Switzerland. The RhAPP 2022 National Conference takes place September 8-10 in Scottsdale, Arizona, highlighting two posters related to quality of life and glucocorticoid toxicity. Concurrently, the Medscape LIVE! conference in Las Vegas will also present two posters on similar topics during the same dates.
ChemoCentryx, Inc. (CCXI) announced the cancellation of its Q2 2022 financial results conference call, originally set for August 9, 2022. This decision follows Amgen's agreement to acquire ChemoCentryx, announced on August 4, 2022. On August 8, 2022, ChemoCentryx filed its Quarterly Report on Form 10-Q for the quarter ended June 30, 2022.
ChemoCentryx specializes in developing oral therapeutics for inflammatory and autoimmune diseases, with TAVNEOS® (avacopan) as its leading product. The company is focused on expanding its pipeline with CCX559, a PD-L1 checkpoint inhibitor, moving into Phase Ib/II studies later in 2022.